



LUND UNIVERSITY

The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells

Bengtsson, Astrid; Jönsson, Gunilla; Magnusson, Cecilia; Salim, Tavga; Axelsson, Cecilia; Sjölander, Anita

Published in:
BMC Cancer

DOI:
[10.1186/1471-2407-13-336](https://doi.org/10.1186/1471-2407-13-336)

2013

[Link to publication](#)

Citation for published version (APA):

Bengtsson, A., Jönsson, G., Magnusson, C., Salim, T., Axelsson, C., & Sjölander, A. (2013). The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells. *BMC Cancer*, 13, Article 336. <https://doi.org/10.1186/1471-2407-13-336>

Total number of authors:
6

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

RESEARCH ARTICLE

Open Access

The cysteinyl leukotriene 2 receptor contributes to all-*trans* retinoic acid-induced differentiation of colon cancer cells

Astrid M Bengtsson^{2†}, Gunilla Jönsson^{1†}, Cecilia Magnusson¹, Tavga Salim¹, Cecilia Axelsson¹ and Anita Sjölander^{1*}

Abstract

Background: Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators that are increased in samples from patients with inflammatory bowel diseases (IBDs). Individuals with IBDs have enhanced susceptibility to colon carcinogenesis. In colorectal cancer, the balance between the pro-mitogenic cysteinyl leukotriene 1 receptor (CysLT₁R) and the differentiation-promoting cysteinyl leukotriene 2 receptor (CysLT₂R) is lost. Further, our previous data indicate that patients with high CysLT₁R and low CysLT₂R expression have a poor prognosis. In this study, we examined whether the balance between CysLT₁R and CysLT₂R could be restored by treatment with the cancer chemopreventive agent all-*trans* retinoic acid (ATRA).

Methods: To determine the effect of ATRA on CysLT₂R promoter activation, mRNA level, and protein level, we performed luciferase gene reporter assays, real-time polymerase chain reactions, and Western blots in colon cancer cell lines under various conditions.

Results: ATRA treatment induces CysLT₂R mRNA and protein expression without affecting CysLT₁R levels. Experiments using siRNA and mutant cell lines indicate that the up-regulation is retinoic acid receptor (RAR) dependent. Interestingly, ATRA also up-regulates mRNA expression of leukotriene C₄ synthase, the enzyme responsible for the production of the ligand for CysLT₂R. Importantly, ATRA-induced differentiation of colorectal cancer cells as shown by increased expression of MUC-2 and production of alkaline phosphatase, both of which could be reduced by a CysLT₂R-specific inhibitor.

Conclusions: This study identifies a novel mechanism of action for ATRA in colorectal cancer cell differentiation and demonstrates that retinoids can have anti-tumorigenic effects through their action on the cysteinyl leukotriene pathway.

Keywords: All-*trans* retinoic acid (ATRA), CysLT₂R, Leukotriene, Leukotriene receptor, Colon cancer, Inflammation

Background

Individuals with inflammatory bowel diseases (IBD) have a 30-50% increased risk of developing colorectal cancer [1,2]. The pro-inflammatory cysteinyl leukotrienes (CysLTs) LTC₄, LTD₄, and LTE₄ are derived from arachidonic acid through the actions of 5-lipoxygenase and leukotriene C₄ synthase (LTC₄S) [3]. The CysLTs can induce smooth muscle constriction, vascular leakage, and eosinophil recruitment in inflammatory diseases such as

asthma and rhinitis (reviewed in [4]). High levels of leukotrienes have been detected in urine from patients with IBDs including ulcerative colitis and Crohn's disease [5,6], and treatment with the 5-lipoxygenase inhibitor Zileuton significantly alleviates IBD symptoms [7]. Importantly, an increased risk for colorectal cancer has been observed in IBD patients [2].

CysLT signaling is initiated when a ligand binds one of the two different G-protein-coupled receptors: CysLT₁R, CysLT₂R [8,9]. Activation of the CysLT₁R triggers signaling through either or both the Gq- and the Gi-protein depending on the cell type, most commonly through Gq [10-12]. We have shown that LTD₄ via CysLT₁R can

* Correspondence: anita.sjolander@med.lu.se

†Equal contributors

¹Department of Laboratory Medicine, Cell and Experimental Pathology, Lund University, Malmö University Hospital, SE-205 02, Malmö, Sweden
Full list of author information is available at the end of the article

induce both Erk phosphorylation and protein kinase C activation that is involved in the regulation of the calcium signal [13,14]. These activities lead to increased proliferation, survival, and phosphatidylinositol 3-kinase- and Rac-dependent migration of colorectal cancer cells [15-17]. In contrast, CysLT₂R promotes colorectal cancer cell differentiation by increasing the activity of the intestinal brush border enzymes alkaline phosphatase and aminopeptidase N [18]. The two receptors also have opposite functions in mast cells, where CysLT₂R negatively regulates the mitogenic responses of CysLT₁R [19]. The combination of high CysLT₁R expression and low CysLT₂R expression in colon cancer specimens is correlated with poor survival prognosis and disease outcome [18,20].

Vitamin A (retinol) and its metabolites are commonly referred to as retinoids. Retinoids play important roles in embryonic development, vision, and as cancer chemopreventive agents (see review [21,22]). All-*trans* retinoic acid (ATRA) is a potent metabolite of vitamin A and is successfully used to treat patients with acute promyelocytic leukemia [23]. In clinical trials, retinoids have also shown promising results in head and neck, skin, ovarian, prostate, and lung cancer [23]. ATRA has also had positive results in animal models for cancer. For instance, rats on a low-fat diet supplemented with vitamin A have a reduced tumor incidence [24]. Moreover, retinoids are effective in reducing azoxymethane-induced aberrant crypt foci and colon tumors in rats [25]. ATRA treatment also reduced tumor growth 40–60% in athymic mice implanted with HT-29 colon carcinoma cells [26]. In human colon cancer cell lines, ATRA is capable of inducing growth inhibition, apoptosis, and differentiation [27].

ATRA exerts its effects through heterodimers of retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which are transcription factors of the nuclear receptor family [23]. All of the known RAR isoforms (α , β , and γ) are expressed in colorectal cancer cell lines [28]. The RAR/RXR heterodimers bind constitutively to retinoic acid response elements (RAREs) in promoters of genes; these are characterized by two consensus half sites [PuG(G/T)TCA] generally arranged as direct repeats separated by 2 to 5 nucleotides [23]. Upon ligand binding, coactivators of the p160 family are recruited to replace the corepressors SMRT and NCoR, and transcription is initiated [23].

We found sequences in the CysLT₂R promoter region that were identical to RAREs reported in the literature and hypothesized that treatment of colorectal cancer cells with ATRA would affect the expression of CysLT₂R. Furthermore, we investigated whether ATRA-induced colon cancer cell differentiation was dependent on CysLT₂R. LTC₄S conjugates LTA₄ with glutathione to form LTC₄ [3], and is induced by ATRA in rat basophilic leukemia cells and associated with subsequent cell

differentiation [29]. In addition to CysLT₂R, LTC₄S could be induced by ATRA in colon cancer cells. It is well established that retinoids are effective inducers of differentiation in cancer cells, but few studies have addressed the pathways that mediate these effects.

Methods

Reagents

LTC₄ was obtained from Cayman Chemicals Co. (Ann Arbor, MI); AP 100984 was a gift from Jilly F. Evans (Amira Pharmaceuticals); and Lipofectamine 2000, Lipofectamine LTX, and Opti-MEM were from Invitrogen (Carlsbad, CA). Hybond polyvinylidene difluoride (PVDF) membranes were from Amersham Biosciences (Little Chalfont, Bucks, UK) and Mini-PROTEAN TGX gels, Immun-blot PVDF membranes and Immun Star Western C were from Biorad (Hercules, CA). The rabbit polyclonal CysLT₁R and CysLT₂R antibodies were obtained from Innovagen (Lund, Sweden). The antibodies RAR α C-20 (sc-551), RAR β C-19 (sc-552) and Lamin B C-20 (sc-6216), were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The secondary peroxidase-conjugated goat anti-rabbit, rabbit anti-goat and anti-mouse antibodies were purchased from Dako Cytomation (Glostrup, Denmark). The caspase-3 fluorometric substrate was obtained from Upstate (Lake Placid, NY). All other reagents were obtained from Sigma Chemicals (St Louis, MO).

Cell culture

The colon cancer cell lines Caco-2, SW480 (ATRA-sensitive), and HCT-116 (ATRA-resistant) [30] were grown in Dulbecco's modified Eagle medium with 100 μ M non-essential amino acids, RPMI 1640, and McCoy's 5A medium, respectively. All media were supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 55 IU/mL penicillin, 55 μ g/mL streptomycin, and 1.5 μ g/mL fungizone (Invitrogen). The cell lines were kept at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. All experiments were performed on day 4–5 after seeding and all ATRA stimulations were performed in the dark. The cells were left in 1.5% FBS or serum-free medium overnight to synchronize the cells and were subsequently treated with 1 or 10 μ M ATRA, 40 nM LTC₄, 1 μ M AP 100984, and/or 2 mM sodium butyrate for the time points indicated. Inhibitors were added 30 min before ATRA stimulation. For time courses, all cells were harvested at the same time.

Western blot

Except for siRNA experiments, whole cell lysates were used for Western blot analysis of CysLT₁R and CysLT₂R. Cells were harvested in Tris lysis buffer on ice supplemented with 1% (v/v) Triton X-100 and protease inhibitors and homogenized 10 times with a Dounce

homogenizer and centrifuged at $200 \times g$ for 10 min. The supernatant was centrifuged at $1000 \times g$ for 5 min to remove cell debris. For Western blot experiments analyzing, RAR α , and RAR β , a Nuclear Extraction kit (Merck Millipore) was used according to the supplier's instruction and CysLT₂R membrane fractions were prepared as in [18]. The Coomassie/Bradford method (Pierce) was used to determine protein content, and equivalent protein amounts for each sample were used. Gel electrophoresis and immunoblotting was performed as described in [31] and the blots were scanned in a Molecular Imager ChemiDoc XRS+ with Image Lab software (Biorad). Stripping of the membranes was performed according to the supplier's instructions (Re-blot Plus, Merck Millipore) and reprobed in the same way.

qPCR analysis

Cells for RNA isolation were washed twice in PBS and immediately frozen at -80°C . The cells were scraped in the lysis buffer provided in the RNeasy Plus Mini kit (Qiagen GmbH) and homogenized 10 times with a 20-G needle. The RNA was isolated and purified according to the supplier's instructions. In short, genomic DNA was removed and RNA was bound to RNeasy spin columns, washed, and dissolved in RNase-free water. cDNA synthesis was performed using RevertAid H Minus M-MuLV reverse transcriptase and oligo(dT)₁₈ primers (Fermentas, Burlington, Canada). The mRNA expression levels of CysLT₁R, CysLT₂R, LTC₄ synthase, mucin-2 (MUC-2), RAR α , and the endogenous reference gene HPRT-1 were quantified using MaximaTM Probe qPCR Master Mix (2x) (Fermentas). The cDNA was mixed with 0.9 μM TaqMan primers and master mix and amplified at 60°C in a Mx3005P thermocycler (Stratagene). The following Taqman primer sets (Applied Biosystems) were used: CYSLTR1, Hs00929113_m1; CYSLTR2, Hs00252658_s1; MUC2, Hs00159374_m1; LTC₄S, Hs00168529_m1; RARA, Hs00940446_m1; RARB, Hs00977140_m1; and HPRT-1, Hs99999909_m1. The samples were analyzed and normalized against HPRT-1 using the MxPro software (Stratagene).

siRNA experiments

Transient siRNA transfections of SW480 cells were carried out according to the manufacturer's instructions. Briefly, 3 days after seeding and at approximately 50% confluence, cells were transfected for 4–6 h in Opti-MEM with reduced-serum without antibiotics, with a mixture of Lipofectamine 2000, and 50–100 nM RAR α , RAR β , or control (non-targeting) siRNA. Human RAR α (sc-29465), RAR β siRNA (sc-29466), and control siRNA-A, -B, and -C (sc-37007, sc-44230, sc-44231 respectively) were from Santa Cruz Biotechnology and ON-TARGET *plus* SMARTpool L-003437-00-0005, L-003438-00-005

and ON-TARGET *plus* Non-Targeting Pool D-001810-10-05, from Dharmacon. The cells were allowed to rest for at least 24 h in complete medium, left in 1.5% FBS or serum-free medium overnight, and stimulated on day 5 as described above.

Alkaline phosphatase activity

Alkaline phosphatase activity was measured using disodium *p*-nitrophenyl phosphate as the substrate. Caco-2 cells were seeded in Petri dishes and incubated for 24 h at 37°C in complete Dulbecco's modified Eagle medium that was ultraviolet-treated to remove any traces of endogenous retinoids. ATRA (1 μM) and/or AP 100984 (1 μM) were added and the cells were incubated for a total of 72 h at 37°C . Every 24 h, the medium was renewed and ATRA and/or AP 100984 were added as before. Sodium butyrate (2 mM) was used as a positive control (data not shown). Five replicates per sample of scraped and lysed cells (PBS, 0.5% Triton X-100) were added to a 96-well plate. The alkaline phosphatase activity was estimated after incubation with disodium *p*-nitrophenyl phosphate for 30 min at 37°C by measuring the absorbance at 405 nm due to formation of *p*-nitrophenol. The assay was performed as previously described in [32]. The samples were normalized for equal protein content.

ELISA LTC₄

SW480 cells were grown for 5 days in normal medium containing 10% serum after which the medium was changed to 1.5% serum containing medium and treated with or without 1 μM ATRA for 24 h. The media were then collected and separated by solid-phase extraction. LTC₄ from the samples were measured using the LTC₄ ELSA kit from Cayman.

Thymidine incorporation assay

Five thousand SW480 cells per well were seeded and cultured for 2 days in flat-bottomed, 96-well plates. Cells were serum starved overnight and subsequently stimulated for 48 h with 1 μM ATRA in the presence or absence of 1 μM AP 100984 (CysLT₂R inhibitor) or with medium containing 10% serum as a positive control for proliferation. Cellular DNA synthesis was assessed by adding 0.5 μCi ³H-thymidine (GE Healthcare) during the final 18 h of stimulation. The cells were washed once with PBS and incubated with 0.05% trypsin-EDTA solution for 10 min at 37°C . Cells were harvested, collected on filter paper, and ³H thymidine incorporation was measured in a 1450 Microbeta Trilux liquid scintillation counter (Wallac, Turku, Finland).

Caspase-3 activity

SW480 cells were cultured in 6-well plates for 4 days. Cells were incubated overnight in medium containing 1.5% serum and subsequently stimulated for 48 h with 1 μ M ATRA in the presence or absence of 1 μ M AP 100984. Taxol (100 nM) was used as a positive control for apoptosis. The cells were lysed for 15 min on ice in 300 μ L buffer containing 1% (v/v) Triton X-100, 10 mM Tris-HCl (pH 7.4), 10 mM $\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$ (pH 7.5), 10 mM sodium pyrophosphate, and 130 mM NaCl. Samples (50 μ L) were suspended in reaction buffer (200 μ L 20 mM HEPES, 2 mM dithiothreitol, and 10% glycerol) and added to Nunc Polysorb 96-well plates where a caspase-3 fluorometric substrate, Ac-Asp-Glu-Val-Asp-AMC (3 μ L; Upstate), was subsequently added. The plates were incubated at 37°C for 1 h in the dark, and the fluorescence of each well was measured at 390 nm excitation and 460 nm emission wavelengths using a BMG plate reader (Offenburg, Germany). Triplicate samples were analyzed and adjusted for equal protein content.

Luciferase reporter assay

A *Renilla* control reporter plasmid and a pGL3-Enhancer vector with a luciferase reporter gene containing 1000 base pairs of the *CYSLTR2* gene promoter (-1 to-1012) was used for CysLT₂R activity assays [32]. SW480 cells (5–10 \times 10⁴ per well) were seeded in 12-well plates. Cells were transfected on day 3 with a mixture of the plasmids and Lipofectamine 2000 or LTX in Opti-MEM according to the supplier's instructions. The final DNA amount per well was 1 μ g for the pGL3 plasmid and 50 ng for the *Renilla* control vector. When siRNA was co-transfected, 50 nM per well was used. The transfection medium was changed to complete RPMI 1640 with 10% FBS after 5–6 h and incubated for 24 h. The medium was changed to serum-free or serum-low (1.5%) medium and cells were incubated overnight before stimulation with 10 μ M ATRA. After 48 h of ATRA stimulation, the experiments were finished by rinsing the wells twice with PBS and adding passive lysis buffer from the Dual-Luciferase Reporter Assay System from Promega (Madison, WI). The plates were placed on an orbital shaker at a slow rate for 30 min and frozen (-20°C) until analysis. Firefly and *Renilla* luminescence were measured on a MiniLumat LB 9506 (Berthold Technologies) according to the protocol for the Dual-Luciferase Reporter Assay System and the ratio was calculated.

Immunofluorescence

Cells were seeded on glass cover slips and grown for 3 days before being stimulated with 10 μ M ATRA for 24 h in the absence of serum. The medium was removed and after several washes with PBS the cells were fixed with 4% paraformaldehyde for 15 min and subsequently

permeabilized with 0.1% Triton X-100 for 5 min. Non-specific binding was blocked with 3% goat serum in PBS for 45 min. Cells were incubated with a primary mucin-2 (MUC-2) antibody (Santa Cruz, diluted 1:50) in 1% goat serum/PBS for 1 h followed by incubation with a secondary Alexa-488 antibody (Molecular Probes, diluted 1:500) for 1 h at room temperature. After washing in PBS, the cover slips were mounted on glass slides with fluorescent mounting medium. Confocal microscopy images were recorded using Zeiss LSM 700 (Carl Zeiss Microscopy GmbH, Jena, Germany).

Statistics

Data was analyzed using PRISM® software (GraphPad Software Inc., La Jolla, CA). One-way ANOVA; unpaired one-sample t-test was performed when samples were compared to a control set to 100% or 1. In all other cases, an unpaired t-test was performed. Values of $P < 0.05$ were considered statistically significant.

Results

ATRA treatment increases CysLT₂R expression in colon cancer cells

ATRA is an established differentiation-inducing agent of epithelial cells [33] and we previously found that CysLT₂R signaling also induces differentiation of colon cancer cells [18]. When either SW480 or Caco-2 colon cancer cells were stimulated with 1 μ M ATRA, CysLT₂R mRNA was induced 3 h after treatment (Figure 1A and C). Protein levels of CysLT₂R also increased significantly, peaking at 3 h in SW480 cells and between 3–12 h in Caco-2 cells (Figure 1B and D). Because CysLT₂R has been suggested to have opposing activities to those of CysLT₁R, we next investigated the effect of ATRA on CysLT₁R [18,19]. Unlike CysLT₂R, which seems to play a role in differentiation, CysLT₁R has mitogenic and pro-survival effects [15,16]. High CysLT₁R expression correlates with poor prognosis of colorectal cancer patients [20]. We stimulated SW480 cells with 1 μ M ATRA for 3–24 h, but failed to observe an induction in CysLT₁R expression, at either the mRNA or protein level (Figure 1E and F).

RAR α knockdown decreases ATRA-induced CysLT₂R mRNA and protein expression

RARs are nuclear hormone receptors for ATRA, which upon ligand binding enable the transcription of target genes [33]. Transfection of SW480 cells with siRNA against RAR α , but not RAR β decreased the induction of CysLT₂R mRNA in response to ATRA stimulation (Figure 2A). qPCR analysis showed that RAR α siRNA downregulated RAR α mRNA levels to approximately 50% (Figure 2B). The mRNA expression of RAR β when treated with RAR β siRNA was downregulated to the




Figure 1 (See legend on next page.)

(See figure on previous page.)

Figure 1 CysLT₂R expression in ATRA-treated colon cancer cell lines. Cells were incubated for 3, 12, or 24 h in the absence or presence of 1 μM ATRA as indicated. **(A and C)** qPCR for CysLT₂R expression. Data are normalized to HPRT-1 in SW480 and Caco-2 cells. **(B and D)** Protein expression of CysLT₂R normalized to β-actin in SW480 and Caco-2 cells as determined by Western blot. **(E)** qPCR for CysLT₁R expression in SW480 cells. Data are normalized to HPRT-1. **(F)** Protein expression of CysLT₁R normalized to β-actin in SW480 cells as determined by Western blot. Changes in CysLT₂R expression relative to basal levels in unstimulated cells are shown as mean ± standard error of the mean (SEM; *P < 0.05, **P < 0.01; n.s. = not significant).

same extent (50%) but was less specific, downregulating RARα mRNA to a similar level (data not shown). We used the nuclear fraction for RARs (Figure 2C) and membrane fraction for CysLT₂R (Figure 2D) protein detection. The induction of CysLT₂R protein in the membrane fraction by ATRA was also abolished when siRNA against RARα was added (Figure 2D). The effect of siRNA treatment on the respective protein levels was similar to that observed for the mRNA (i.e., no or little induction after ATRA stimulation; Figure 2A-D).

To study CysLT₂R promoter activity, SW480 cells were transiently transfected with a luciferase reporter gene vector and stimulated with ATRA. A dose response was observed with increasing ATRA concentration (0.1, 1.0, and 10 μM; Figure 2E). Stimulation with 10 μM ATRA was chosen for the inhibition studies in which cells were treated with siRNAs targeting the RARs. Neither RARα siRNA nor RARβ siRNA induced any significant change in basal CysLT₂R promoter activity (Figure 2F). However, in contrast to the activation seen for the regulation of the endogenous CysLT₂R gene (Figure 2D), siRNA knock-down of RARα or RARβ or a combination of the two did not affect the ATRA-induced activation of the transfected partial/putative CysLT₂R promoter (Figure 2F).

ATRA does not affect the proliferation of SW480 colon cancer cells

The effects of ATRA on tumor suppression cannot be entirely attributed to its role in differentiation, as ATRA has also been reported to inhibit growth of some colon cancer cell lines [27,34]. To determine whether ATRA has such an activity in our system, we pre-incubated SW480 cells with or without 1 μM CysLT₂R antagonist AP 100984 and stimulated the cells with 1 μM ATRA or 40 nM LTC₄ for 48 h. DNA synthesis was measured as the amount of ³H-thymidine incorporated during the last 18 h of stimulation. Neither ATRA nor LTC₄, alone or in combination, induced any changes in DNA synthesis compared to unstimulated cells (Figure 3A). Complete medium with 10% FBS was used as a positive control for proliferation and induced a 2-fold increase in ³H-thymidine incorporation. These data showed that neither ATRA nor does the CysLT₂R inhibitor AP 100984 have any effect on SW480 cell growth.

Effects of ATRA on apoptosis, LTC₄S mRNA and LTC₄ expression in SW480 cells

In some cell types, ATRA induces apoptosis through the caspase-3 pathway [35]. We therefore investigated whether ATRA could induce apoptosis in these colon cancer cells. The cells were incubated with or without 1 μM CysLT₂R inhibitor AP 100984 and stimulated with 1 μM ATRA for 48 h. Under these conditions, we were unable to observe apoptosis in SW480 cells as measured by caspase-3 activity (Figure 3B). Taxol was used as a positive control for apoptosis and induced a significant (50%) increase in caspase-3 activity. Neither AP 100984 alone or in combination with ATRA had any effect on caspase-3 activity, indicating that AP 100984 had no intrinsic apoptotic effect.

We next investigated whether ATRA could increase LTC₄S mRNA expression. Cells were stimulated with ATRA for 3, 12 or 24 h and the LTC₄S mRNA level was determined with qPCR. We observed a 4-fold increase of LTC₄S mRNA in cells treated with ATRA for 12 h compared to control cells (Figure 3C). The induction of LTC₄S can enhance LTC₄ production and in turn induce CysLT₂R activation, thus creating a positive feedback loop that promotes differentiation. Therefore, we next examined the endogenous synthesis and release of LTC₄ in SW480 cells, we found a basal release of 140 pg/ml LTC₄ and a possible enhanced release by ATRA to 190 pg/ml LTC₄ in SW480 cells (Figure 3D).

ATRA does not induce CysLT₂R expression in ATRA-resistant HCT-116 cells

The colon cancer cell line HCT-116 is ATRA-resistant [34]. We confirmed this with qPCR, finding that stimulation of HCT-116 cells with 1 μM ATRA failed to induce mRNA expression of CysLT₂R at any of the time points observed (Figure 4A). Likewise, Western blots of lysates harvested from cells treated with 1 μM ATRA for 3, 12, and 24 h showed there was no effect on CysLT₂R protein expression (Figure 4B). In case the effect on the protein level was delayed, we also tested after 48 h of stimulation, but no significant change from the unstimulated cells was observed.




Figure 2 Effect of RARα or RARβ inhibition on CysLT₂R expression and promoter activity. SW480 cells were transfected with control siRNA (non-target siRNA), RARα siRNA, or/and RARβ siRNA, allowed to rest for 24 h, serum-starved overnight, and subsequently stimulated with 10 μM ATRA. **(A and B)** qPCR for CysLT₂R and RARα expression. Data are normalized to HPRT-1 with and without ATRA stimulation for 3 h. **(C)** Western blots without and with ATRA stimulation for 3 h. **(D)** Western blot analyzes of CysLT₂R protein expression in membrane fractions from SW480 cells stimulated or not with ATRA for 3 h normalized to unstimulated control. **(E)** CysLT₂R luciferase promoter activity in cells stimulated with or without ATRA for 48 h. Data are normalized to unstimulated controls. **(F)** CysLT₂R luciferase promoter activity in siRNA-treated cells stimulated with or without ATRA for 48 h. Data are normalized to unstimulated control. Values are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

The CysLT₂R antagonist AP 100984 reduces ATRA-induced MUC-2 expression and alkaline phosphatase activity

Mucins are secreted by colonocytes to form a mucus barrier to protect the intestinal epithelium [36]. MUC-2 is down-regulated in many colorectal cancers and is associated with the differentiated state of colonic epithelia [37]. We analyzed the expression of MUC-2 mRNA in SW480 cells and found that treatment with 1 μM ATRA increased MUC-2 mRNA expression 2-fold after 3 h of stimulation (Figure 5A). When cells were pretreated with 1 μM AP 100984, the ATRA-induced MUC-2 up-regulation was decreased. AP 100984 itself had no effect on MUC-2 mRNA expression. Similarly,


when cells were treated with RARα siRNA, ATRA-induced MUC-2 expression was decreased by approximately 50% (Figure 5B). Thus, ATRA-enhanced MUC-2 expression in SW480 colon cancer cells is at least partly mediated through CysLT₂R and RARα signaling. Furthermore, we also found by immunofluorescence that the MUC-2 protein expression was increased after treatment with ATRA for 24 h (Figure 5C).


Alkaline phosphatase is one of the brush border enzymes expressed in the differentiated epithelial cells of the intestines and alkaline phosphatase activity is often used as a differentiation marker [38]. In accordance with others' results from previous studies, we found that

ATRA is able to significantly induce alkaline phosphatase activity in Caco-2 cells, as determined by the formation of *para*-nitrophenol (Figure 5D) [39]. Sodium butyrate was included as a positive control for alkaline phosphatase activity, and increased the activity approximately 2-fold compared to unstimulated cells (data not shown) [40]. Interestingly, ATRA-induced alkaline phosphatase activity was significantly reduced upon pretreatment for 30 min with 1 μ M CysLT₂R inhibitor AP 100984. Addition of the inhibitor alone did not affect basal alkaline phosphatase activity, suggesting that ATRA's induction of alkaline phosphatase activity is partly mediated through CysLT₂R in Caco-2 cells. Together, the MUC-2 expression and alkaline phosphatase activity studies shows that ATRA's induction of differentiation is at least partially dependent on CysLT₂R signaling.

Discussion

ATRA is well known to induce differentiation of epithelial cells and we have also shown that CysLT₂R induces differentiation of epithelial cells [23,32]. We found putative RAREs within the promoter region of the transcription start of the *CYSLTR2* gene [32]. Based on this finding, we hypothesized that ATRA could induce CysLT₂R expression. We show here that ATRA can indeed induce both mRNA and protein expression of CysLT₂R in two different colon cancer cell lines. Knock-down of RAR α with siRNA decreases ATRA-induced CysLT₂R expression in SW480 cells. In accordance with this finding, ATRA was unable to induce CysLT₂R mRNA or protein expression in HCT-116 colon cancer cells, which lack functional RARs. Neither mutations in these possible response elements nor truncation of the inserted region changed the cell response to ATRA stimulation






(see Additional file 1: Figure S1). Furthermore, a high concentration of ATRA is required to observe any cellular response. Together, these findings might suggest that ATRA's induction of CysLT₂R is mediated indirectly or that the intracellular RAR levels are low. This is in agreement with findings that the relative expression of RAR α is higher than RAR β in human intestine and the overall expression of RARs (especially RAR β 2) is lower in tumors than normal tissue due to epigenetic modifications [28].

Previous studies showed that CysLT₂R can be up-regulated by the cytokines interferon γ (IFN γ) and interleukin-4 in monocytes, T cells, and B cells and by interleukin-13 in monocytes [41,42]. Further, consistent with its role in inflammatory responses. Bai *et al.* [43] have shown that ATRA can down-regulate the colon inflammatory response as measured by tumor necrosis factor alpha (TNF α) levels, in patients with IBD *in vitro* and in a murine colitis model *in vivo*. We previously found that TNF α also down-regulates CysLT₂R while up-regulating CysLT₁R in colon cancer cells [44], an observation that also highlights the importance of maintaining receptor balance in epithelial cells [18].

ATRA has previously been shown to induce mRNA expression, protein expression, and promoter activity of

LTC₄S in rat basophilic leukemia cells. LTD₄ is a ligand for CysLT₁R that up-regulates both LTC₄S and CysLT₂R in intestinal epithelial and colon cancer cells [44]. These activities are associated with differentiation, but the underlying signaling mechanism remained unclear [29]. We show for the first time that ATRA is capable of up-regulating LTC₄S mRNA in epithelial cells. LTC₄S is responsible for the production of the cysteinyl leukotriene LTC₄. Furthermore, ATRA by inducing both CysLT₂R and possibly its ligand, activates a signaling pathway that has beneficial effects on colon epithelial cell differentiation.

MUC-2 and brush border enzymes are typical markers of differentiated colonocytes [45]. We have previously shown that LTC₄ stimulation of CysLT₂R induces differentiation in Caco-2 colon cancer cells, as measured by increased MUC-2 mRNA expression and increased activity of the brush border enzymes alkaline phosphatase and aminopeptidase N [18]. ATRA has also been shown to induce MUC-2 protein via PKC α and CREB in airway human tracheobronchial epithelial cells [46]. Furthermore, rats on a retinoid-deficient diet have decreased MUC-2 mRNA expression in the jejunum, ileum, and colon [47]. These studies indicate that ATRA and



CysLT₂R have similar functions in epithelial differentiation, as evidenced by MUC-2 expression. In the current study, we show that ATRA's ability to induce MUC-2 expression in SW480 colon cancer cells might also involve CysLT₂R signaling, as the effect can be reduced by either a CysLT₂R inhibitor or by RAR α siRNA alone or a combination of RAR α and RAR β siRNA. Moreover, we

found that ATRA-induced alkaline phosphatase activity could be reduced by pretreatment with the same CysLT₂R inhibitor. Our findings indicate that CysLT₂R signaling, likely in concert with other pathways, contributes to ATRA's differentiation-inducing activity.

In addition to being a powerful differentiation-inducing agent, ATRA can inhibit growth in some colon cancer cell lines [48]. Therefore, we investigated whether ATRA primarily affects differentiation in SW480 cells, or also inhibits growth. In HT-29 cells ATRA-induced growth inhibition is mediated by RAR α [49], whereas, in Caco-2 cells it is mediated by RAR β [50]. However, other studies have reported that ATRA has no effect on growth inhibition in HT-29 cells [27]. In certain contexts, ATRA also has the ability to mediate apoptosis [35]. In our study, we were unable to observe any effects of ATRA on growth inhibition or apoptosis in SW480 cells, suggesting that ATRA's main activity in these cells is to induce cell differentiation.

Although the *CYSLTR2* gene has been mapped to chromosome 13q14, a region linked to atopic asthma [9], it remains unclear how the gene is regulated. When studying the promoter region of CysLT₂R, we found a binding site for IRF-7 that showed reporter gene activity upon IFN α stimulation [32]. This finding encouraged us to further investigate whether other regulatory elements in the region were present. This analysis led us to identify, for the first time, putative RARE elements in the promoter region of CysLT₂R. Stimulation with ATRA increased CysLT₂R promoter activity in a reporter gene assay, but neither mutations nor truncations in the RARE elements decreased the activity. In the present study, we found a discrepancy between the regulation of the endogenous CysLT₂R gene activity and the regulation of a transfected partial/putative promoter of the same gene. At present we do not know the reason for this discrepancy, but a couple of explanations can be considered. First, the transfected CysLT₂R promoter is expressed at a level that in comparison with the endogenous promoter is significantly higher and therefore relatively low level of RARs do not have the same ability to regulate its activity as they have when only the endogenous promoter for CysLT₂R is present. Secondly, another possibility is that our transfected putative CysLT₂R promoter is lacking crucial bindings sites for some enhancer/cofactor that is vital for its proper regulation. Thirdly, in addition to direct ligand-dependent transcription of genes, there can be indirect effects such transactivation of other transcription factors independently of any RAR and also non-genomic mechanisms of action of ATRA [51]. Finally, our data might suggest that the effect of ATRA on CysLT₂R promoter activity is indirect and does not involve these putative RARs. Clearly, this issue requires extensive future work before it can be resolved.

Most of the studies investigating the role of RAREs in promoters have focused on proteins involved in retinoid transport or catabolism [52,53] or developmental regulation, where ATRA is considered a 'master switch' for differentiation. For example, ATRA induces *hoxb1* expression, a gene responsible for gut development in mouse embryos [54]. Other ATRA-induced transcription factors or cofactors include STAT-1, Oct3/4, Hoxa1, and Hoxb4 [53,55]. Retinoids also have the ability to repress genes. In a mouse epidermal cell line, retinoids block tumor promotion by inhibiting AP-1 [56]. Interestingly, we previously observed that signaling through CysLT₁R induces activation of the AP-1 pathway in intestinal epithelial cells, leading to increased proliferation [57]. Here we show that expression of CysLT₁R is unaffected by ATRA treatment. High CysLT₁R expression in cancer patients is not restricted to colorectal cancer cells; it has also been observed in transitional cell carcinoma of the bladder [58], neuroblastoma [59], astrocytoma [60], and in classical Hodgkin's lymphoma [61]. ATRA's mechanism of action on cysteinyl leukotriene receptors may also highlight a signaling pathway that contributes to other cancer types.

We show for the first time that in human colon cancer cells, the differentiation agent ATRA acts in part by inducing both LTC₄S, an enzyme responsible for the generation of CysLTs, and CysLT₂R, a receptor for these ligands. Furthermore, we report that this effect is very likely mediated through RAR α or a combination of RAR α and RAR β and presumably acts through a mediator that can regulate CysLT₂R. ATRA-induced differentiation can partially be reduced by a CysLT₂R inhibitor, implying that CysLT₂R contributes to this differentiation. Finally, ATRA does not induce expression of the pro-mitogenic CysLT₁R.

Conclusions

We suggest here a mechanism by which ATRA induces differentiation, in part by increasing CysLT₂R expression. Our data shed new light on how ATRA exerts its effects on colorectal cancer cell differentiation and demonstrates that retinoids are able to delicately regulate the balance between different elements in the cysteinyl leukotriene pathway. Further work is necessary to elucidate the interplay between retinoids and eicosanoids, but the knowledge gained from such studies could yield new insights for designing colon cancer therapy regimens.

Additional file

Additional file 1: Figure S1. CysLT₂R luciferase activity in SW480 cells transfected with a vector containing mutated putative RARE sites or truncations.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AB, GJ and AS conceived and designed the study. AB, GJ, CA, TS and CM performed the experiments and analyzed the data. AB, GJ, and AS drafted the paper. All authors read and approved the final manuscript.

Acknowledgements

We thank Jilly F. Evans at Amira Pharmaceuticals for providing the CysLT₂ inhibitor AP 100984. This study was supported by grants to A.S. from the Swedish Cancer Foundation, the Swedish Medical Research Council, the Foundations at Malmö University Hospital, the Gunnar Nilsson Foundation, and the Österlund Foundation, and to A.B. and C.M. from the Royal Physiographic Society in Lund.

Author details

¹Department of Laboratory Medicine, Cell and Experimental Pathology, Lund University, Malmö University Hospital, SE-205 02, Malmö, Sweden. ²Present name and address, Astrid Friborg at Berries by Astrid, Stockholm, Sweden.

Received: 23 October 2012 Accepted: 24 June 2013

Published: 8 July 2013

References

1. Eaden J: **Review article: colorectal carcinoma and inflammatory bowel disease.** *Aliment Pharmacol Ther* 2004, **20**(Suppl 4):24–30.
2. Ekbo M, Helmick C, Zack M, Adami HO: **Ulcerative colitis and colorectal cancer. A population-based study.** *N Engl J Med* 1990, **323**(18):1228–1233.
3. Nakamura M, Shimizu T: **Leukotriene receptors.** *Chem Rev* 2011, **111**(10):6231–6298.
4. Singh RK, Gupta S, Dastidar S, Ray A: **Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.** *Pharmacology* 2010, **85**(6):336–349.
5. Sharon P, Stenson WF: **Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.** *Gastroenterology* 1984, **86**(3):453–460.
6. Kim JH, Tagari P, Griffiths AM, Ford-Hutchinson A, Smith C, Sherman PM: **Levels of peptidoleukotriene E4 are elevated in active Crohn's disease.** *J Pediatr Gastroenterol Nutr* 1995, **20**(4):403–407.
7. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K: **5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.** *Agents Actions* 1992:37–46.
8. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, et al: **Characterization of the human cysteinyl leukotriene CysLT1 receptor.** *Nature* 1999, **399**(6738):789–793.
9. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, et al: **Characterization of the human cysteinyl leukotriene 2 receptor.** *J Biol Chem* 2000, **275**(39):30531–30536.
10. Capra V, Ravasi S, Accomazzo MR, Citro S, Grimoldi M, Abbracchio MP, Rovati GE: **CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation.** *J Cell Sci* 2005, **118**(Pt 23):5625–5636.
11. Nielsen CK, Massoumi R, Sonnerlind M, Sjolander A: **Leukotriene D4 activates distinct G-proteins in intestinal epithelial cells to regulate stress fibre formation and to generate intracellular Ca²⁺ mobilisation and ERK1/2 activation.** *Exp Cell Res* 2005, **302**(1):31–39.
12. Adolfsson JL, Ohd JF, Sjolander A: **Leukotriene D4-induced activation and translocation of the G-protein alpha i3-subunit in human epithelial cells.** *Biochem Biophys Res Commun* 1996, **226**(2):413–419.
13. Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjolander A: **Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells.** *J Cell Sci* 2002, **115**(Pt 9):1883–1893.
14. Thodeti CK, Nielsen CK, Paruchuri S, Larsson C, Sjolander A: **The epsilon isoform of protein kinase C is involved in regulation of the LTD(4)-induced calcium signal in human intestinal epithelial cells.** *Exp Cell Res* 2001, **262**(2):95–103.
15. Paruchuri S, Sjolander A: **Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line Int 407.** *J Biol Chem* 2003, **278**(46):45577–45585.

16. Paruchuri S, Broom O, Dib K, Sjolander A: **The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells.** *J Biol Chem* 2005, **280**(14):13538–13544.
17. Ohd JF, Wikstrom K, Sjolander A: **Leukotrienes induce cell-survival signaling in intestinal epithelial cells.** *Gastroenterology* 2000, **119**(4):1007–1018.
18. Magnusson C, Ehrmstrom R, Olsen J, Sjolander A: **An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation.** *Cancer Res* 2007, **67**(19):9190–9198.
19. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA: **CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells.** *Blood* 2007, **110**(9):3263–3270.
20. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A: **Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas.** *Gastroenterology* 2003, **124**(1):57–70.
21. Niederreither K, Dolle P: **Retinoic acid in development: towards an integrated view.** *Nat Rev Genet* 2008, **9**(7):541–553.
22. Mongan NP, Gudas LJ: **Diverse actions of retinoid receptors in cancer prevention and treatment.** *Differentiation* 2007, **75**(9):853–870.
23. Clarke N, Germain P, Altucci L, Gronemeyer H: **Retinoids: potential in cancer prevention and therapy.** *Expert Rev Mol Med* 2004, **6**(25):1–23.
24. Newberne PM, Bueche D, Riegropitak S, Schragr TF: **The influence of dietary levels of vitamin A and fat on colon cancer.** *Nutr Cancer* 1990, **13**(4):235–242.
25. Zheng Y, Kramer PM, Olson G, Lubet RA, Steele VE, Kelloff GJ, Pereira MA: **Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats.** *Carcinogenesis* 1997, **18**(11):2119–2125.
26. Paulsen JE, Lutzow-Holm C: **In vivo growth inhibition of human colon carcinoma cells (HT-29) by all-trans-retinoic acid, difluoromethylornithine, and colon mitosis inhibitor, individually and in combination.** *Anticancer Res* 2000, **20**(5B):3485–3489.
27. Lee MO, Han SY, Jiang S, Park JH, Kim SJ: **Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta.** *Biochem Pharmacol* 2000, **59**(5):485–496.
28. Modica S, Gofflot F, Murzilli S, D'Orazio A, Salvatore L, Pellegrini F, Nicolucci A, Tognoni G, Copetti M, Valanzano R, et al: **The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors.** *Gastroenterology* 2010, **138**(2):636–648. 648 e631–612.
29. Abe M, Shibata K, Urata H, Sakata N, Katsuragi T: **Induction of leukotriene C4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone.** *J Cell Physiol* 2003, **196**(1):154–164.
30. Park EY, Wilder ET, Lane MA: **Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels.** *Nutr Cancer* 2007, **57**(1):66–77.
31. Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, Sjolander A: **A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells.** *Cancer Res* 2005, **65**(3):732–742.
32. Magnusson C, Bengtsson AM, Liu M, Liu J, Ceder Y, Ehrmstrom R, Sjolander A: **Regulation of cysteinyl leukotriene receptor 2 expression—a potential anti-tumor mechanism.** *PLoS One* 2011, **6**(12):e29060.
33. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM: **Retinoids in chemoprevention and differentiation therapy.** *Carcinogenesis* 2000, **21**(7):1271–1279.
34. Park EY, Dillard A, Williams EA, Wilder ET, Pepper MR, Lane MA: **Retinol inhibits the growth of all-trans-retinoic acid-sensitive and all-trans-retinoic acid-resistant colon cancer cells through a retinoic acid receptor-independent mechanism.** *Cancer Res* 2005, **65**(21):9923–9933.
35. Gumireddy K, Sutton LN, Phillips PC, Reddy CD: **All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway.** *Clin Cancer Res* 2003, **9**(11):4052–4059.
36. Sheng YH, Hasnain SZ, Florin TH, McGuckin MA: **Mucins in inflammatory bowel diseases and colorectal cancer.** *J Gastroenterol Hepatol* 2012, **27**(1):28–38.
37. Byrd JC, Bresalier RS: **Mucins and mucin binding proteins in colorectal cancer.** *Cancer Metastasis Rev* 2004, **23**(1–2):77–99.
38. Olsen L, Bressendorff S, Troelsen JT, Olsen J: **Differentiation-dependent activation of the human intestinal alkaline phosphatase promoter by HNF-4 in intestinal cells.** *Am J Physiol Gastrointest Liver Physiol* 2005, **289**(2):G220–226.
39. Bartolini G, Ammar K, Mantovani B, Scanabissi F, Ferreri AM, Rocchi P, Orlandi M: **Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoic acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29.** *Anticancer Res* 2004, **24**(3a):1779–1783.
40. Wang Q, Wang X, Hernandez A, Kim S, Evers BM: **Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.** *Gastroenterology* 2001, **120**(6):1381–1392.
41. Early SB, Barezzi E, Negri J, Hise K, Borish L, Steinke JW: **Concordant Modulation of Cysteinyl Leukotriene Receptor Expression by IL-4 and IFN- γ on Peripheral Immune Cells.** *Am J Respir Cell Mol Biol* 2007, **36**(6):715–720.
42. Shirasaki H, Seki N, Fujita M, Kikuchi M, Kanaizumi E, Watanabe K, Himi T: **Agonist- and T(H)2 cytokine-induced up-regulation of cysteinyl leukotriene receptor messenger RNA in human monocytes.** *Ann Allergy Asthma Immunol* 2007, **99**(4):340–347.
43. Bai A, Lu N, Guo Y, Liu Z, Chen J, Peng Z: **All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis.** *J Leukoc Biol* 2009, **86**(4):959–969.
44. Yudina Y, Parhamifar L, Bengtsson AM, Juhas M, Sjolander A: **Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells.** *Prostaglandins Leukot Essent Fatty Acids* 2008, **79**(6):223–231.
45. Smith AC, Podolsky DK: **Colonic mucin glycoproteins in health and disease.** *Clin Gastroenterol* 1986, **15**(4):815–837.
46. Kim SW, Hong JS, Ryu SH, Chung WC, Yoon JH, Koo JS: **Regulation of mucin gene expression by CREB via a nonclassical retinoic acid signaling pathway.** *Mol Cell Biol* 2007, **27**(19):6933–6947.
47. Amit-Romach E, Uni Z, Cheled S, Berkovich Z, Reifan R: **Bacterial population and innate immunity-related genes in rat gastrointestinal tract are altered by vitamin A-deficient diet.** *J Nutr Biochem* 2009, **20**(1):70–77.
48. Nicke B, Riecken EO, Rosewicz S: **Induction of retinoic acid receptor beta mediates growth inhibition in retinoid resistant human colon carcinoma cells.** *Gut* 1999, **45**(1):51–57.
49. Nicke B, Kaiser A, Wiedenmann B, Riecken EO, Rosewicz S: **Retinoic acid receptor alpha mediates growth inhibition by retinoids in human colon carcinoma HT29 cells.** *Biochem Biophys Res Commun* 1999, **261**(3):572–577.
50. McCormack SA, Viar MJ, Tague L, Johnson LR: **Altered distribution of the nuclear receptor RAR beta accompanies proliferation and differentiation changes caused by retinoic acid in Caco-2 cells.** *In Vitro Cell Dev Biol Anim* 1996, **32**(1):53–61.
51. Blomhoff R, Blomhoff HK: **Overview of retinoid metabolism and function.** *J Neurobiol* 2006, **66**(7):606–630.
52. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N: **Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors.** *Cell* 2007, **129**(4):723–733.
53. Freemantle SJ, Spinella MJ, Dmitrovsky E: **Retinoids in cancer therapy and chemoprevention: promise meets resistance.** *Oncogene* 2003, **22**(47):7305–7315.
54. Ross SA, McCaffery PJ, Drager UC, De Luca LM: **Retinoids in embryonal development.** *Physiol Rev* 2000, **80**(3):1021–1054.
55. McCaffery P, Drager UC: **Regulation of retinoic acid signaling in the embryonic nervous system: a master differentiation factor.** *Cytokine Growth Factor Rev* 2000, **11**(3):233–249.
56. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH: **Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.** *Proc Natl Acad Sci USA* 1994, **91**(2):609–613.
57. Bengtsson AM, Massoumi R, Sjolander A: **Leukotriene D(4) induces AP-1 but not NFkappaB signaling in intestinal epithelial cells.** *Prostaglandins Other Lipid Mediat* 2007, **85**(3–4):100–106.
58. Matsuyama M, Funao K, Hayama T, Tanaka T, Kawahito Y, Sano H, Takemoto Y, Nakatani T, Yoshimura R: **Relationship Between Cysteinyl-Leukotriene-1 Receptor and Human Transitional Cell Carcinoma in Bladder.** *Urology* 2009, **73**(4):916–921.
59. Sveinbjornsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, Ponthan F, Orrego A, Haeggstrom JZ, Johnsen JI, Kogner P: **Expression of enzymes**

and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. *FASEB J* 2008, **22**(10):3525–3536.

60. Zhang WP, Hu H, Zhang L, Ding W, Yao HT, Chen KD, Sheng WW, Chen Z, Wei EQ: **Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors.** *Neurosci Lett* 2004, **363**(3):247–251.
61. Schain F, Tryselius Y, Sjoberg J, Porwit A, Backman L, Malec M, Xu D, Vockerodt M, Baumforth KR, Wei W, *et al*: **Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma.** *Int J Cancer* 2008, **123**(10):2285–2293.

doi:10.1186/1471-2407-13-336

Cite this article as: Bengtsson *et al.*: The cysteinyl leukotriene 2 receptor contributes to all-*trans* retinoic acid-induced differentiation of colon cancer cells. *BMC Cancer* 2013 **13**:336.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

